Desire Is Not Arousal, and Neither One Is Function
Three separate things arrive in the consultation under one word. The first is wanting — whether sex occurs to you at all. The second is arousal — whether the body switches on once it is on the table. The third is function — whether the mechanics complete. They are produced by different biology, they fail for different reasons, and the treatments that work on one of them do essentially nothing for the other two.
Almost everyone arrives having collapsed the three into a single complaint, usually the word libido. That is not a failure of vocabulary; it is how the experience feels from the inside. But which of the three actually changed is the question that decides everything downstream, and getting it wrong is the most reliable way to spend money on a treatment that was never aimed at the problem.
The three things that get called one thing
Wanting is motivational. It runs on reward circuitry in the brain, on hormonal tone, and on everything that feeds those — sleep, mood, stress, medications, alcohol, and the ordinary weather of a life. When wanting goes, sex does not so much become difficult as stop being a category you think in. People describe it as indifference rather than frustration.
Arousal is the body responding to a sexual stimulus: blood flow to genital tissue, lubrication in women, engorgement in men, the shift in attention and breathing that goes with it. It is largely autonomic, meaning it is not obedient to intention. It requires a parasympathetic state, which is why anxiety — a sympathetic state — opposes it so efficiently.
Function is whether the response holds and completes: an erection firm enough and lasting long enough, orgasm arriving when it is wanted rather than too soon, too late or not at all. This is the most mechanical of the three, and the one with the best-defined treatments.
The diagnostic literature has never been fully settled on where the lines fall, which is itself informative. The current psychiatric classification keeps desire and erectile difficulty as separate diagnoses in men, and in women merges desire and arousal into one — because in women the two are so entangled in practice that clinicians could not reliably tell them apart.
The body and the mind do not always agree
This is the part that surprises people, and it resolves a great deal of unnecessary worry.
Genital response and felt arousal correlate poorly. The body can respond while very little is felt, and someone can be thoroughly interested while the body declines to cooperate. The mismatch is larger in women than in men on average, but it exists in both.
Three practical consequences follow, and all three matter.
Lubrication is not a desire reading. Its absence does not mean a woman is uninterested, and its presence does not mean she is. After menopause it mostly measures tissue and blood supply, which is a separate problem with a separate and rather good treatment — see painful sex after menopause.
An erection is not a desire reading either. Men lose morning erections for vascular and sleep-related reasons while wanting is entirely intact, and men with flattened desire frequently still have perfectly serviceable erections. One does not certify the other.
And a body that responds does not settle the question of whether something is wrong. "Everything works, I just never think about it" is a complete and coherent complaint. It is a wanting problem with an intact response, and it has its own causes, most of which are on the list the low libido hub sets out.
Which one changed: the questions that separate them
A clinician works this out with history rather than a test, and the questions are unglamorous.
Does it happen alone as well as with a partner? A response that is present during masturbation and absent with a partner points away from plumbing and toward context, anxiety or the relationship. A response that has gone everywhere, in every setting, points toward something systemic — vascular, hormonal, pharmacological.
Was the change abrupt or gradual? Vascular and hormonal decline is slow, measured in years. An abrupt change dated to a particular season is a medication, an illness, a new stressor or a new sleep problem until proven otherwise.
Which came first? Wanting that faded and took the response with it runs in one direction. A response that failed, generated dread, and then killed the wanting runs in the other — and that second sequence is extremely common in men and routinely misread as primary low desire.
Is the wanting absent, or only un-prompted? Many people who report no desire have desire that arrives after arousal rather than before it. That is a pattern, not a deficiency, and it is different enough to have its own page.
Why the distinction is expensive to get wrong
Each of the available treatments acts on one system. None of them acts on all three.
A PDE5 inhibitor — tadalafil, sildenafil — relaxes vascular smooth muscle so that more blood enters in response to arousal. It is the best-evidenced thing in this category and it does nothing whatsoever for wanting. Taken against a desire complaint it produces an expensive disappointment. One absolute rule attaches to the class: with any nitrate — nitroglycerin in any form, isosorbide mononitrate or dinitrate, or amyl nitrite ("poppers") — the combination can cause a severe and potentially fatal drop in blood pressure. That is a contraindication, not a risk to be weighed.
Testosterone in a man who is genuinely deficient and symptomatic acts on wanting. It does not reliably restore an erection, and prescribing it for that alone is treating the wrong system. See low testosterone.
PT-141 (bremelanotide) acts centrally, on the desire side rather than the blood flow side. It is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and that is the whole of its approval. Use in men, in postmenopausal women, or as part of a compounded combination falls outside it, and compounded preparations are not reviewed by the FDA for safety or effectiveness. Who should not take PT-141 is the honest version of the exclusion list.
Vaginal estrogen treats tissue. Where the real complaint is discomfort, it addresses the cause of the avoidance rather than arguing with the avoidance.
And there is a fifth option that is not a product: treating what is driving the change. The reviewed medication list, the sleep study, the drink fewer nights a week. Those work on the system that is actually affected, which is the only thing any of these have in common.
Frequently asked questions
Libido is wanting; erectile difficulty is a mechanical failure of the response. They are separate systems with separate causes, and one does not cause the other in either direction — although a failed response often produces anxiety that goes on to suppress wanting.
It is common and it is not a disorder in itself. Genital response and felt arousal correlate poorly, particularly in women. It is worth raising if it is a change from your own baseline and it bothers you.
Toward arousal or function rather than desire — which means blood flow, nerves, tissue, hormones and medications, and in men a cardiovascular question worth taking seriously. See erectile changes at 50.
Not reliably. It acts on desire. Where a man is genuinely deficient it may help function indirectly, but it is not an erection treatment and it is monitored therapy rather than a one-off.
No. It improves blood flow in response to arousal that is already there. This is the single most common misunderstanding about the drug class.
That is what the assessment is for, and the history answers it more often than a test does. The most useful things you can supply are when the change started and whether it is the same alone as it is with a partner.
Where this fits in your plan
If you take one thing from this page into the assessment, make it the answer to two questions: which of the three changed, and what else changed at the same time. Those two answers narrow the list faster than any panel, and they are the part only you can supply.
From here, the next page depends on which way you answered. If the wanting is intact but un-prompted, read responsive versus spontaneous desire. If the change was abrupt, start with medications that lower libido. If you want to know what a blood test can settle, that is when low desire is worth testing.
We measure first. Then we act.
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition — Sexual Dysfunctions.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Symptoms and Causes of Erectile Dysfunction.
- American College of Obstetricians and Gynecologists. Female Sexual Dysfunction — ACOG Practice Bulletin.
- Vyleesi (bremelanotide) prescribing information — Indications and Usage; Warnings and Precautions.
- Cialis (tadalafil) prescribing information — Contraindications (nitrates).
- The Menopause Society (formerly the North American Menopause Society). Position Statement on the Genitourinary Syndrome of Menopause.
- Back toLow Libido
- Responsive vs spontaneous desireMany people never feel desire out of nowhere — it arrives after arousal. That is a pattern, not a deficiency, and it changes what is worth treating.Read
- Medications that lower libidoAntidepressants, finasteride, some blood pressure drugs, hormonal contraception and opioids all reduce desire. How to tell, and what to ask your prescriber.Read
- When testing is worth itA panel earns its place when a plausible result changes the plan. Where testing genuinely settles low desire, where it does not, and what a normal result means.Read
- When the cause is not in the bloodSleep debt, chronic stress, a changed body, past pain and relationship context all suppress desire and none of them show on a blood test. Taken seriously.Read
- Libido and sexual health guideDesire and function are different systems with different causes — what changes in midlife and what is measurable.Read
- Sexual wellnessLibido, comfort and intimacy support for women and men.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
It does not diagnose sexual dysfunction and is not a substitute for examination by a clinician. Do not take a PDE5 inhibitor with any nitrate medication.